Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium

for the Diabetes Prevention Program Research Group

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years. Methods: The DPPOS offered periodic group lifestyle sessions to all participants and continued metformin in the originally randomized metformin group. Subclinical atherosclerosis was assessed in 2029 participants with coronary artery calcium (CAC) measurements after an average of 14 years of follow-up. The CAC scores were analyzed continuously as CAC severity and categorically as CAC presence (CAC score >0) and reported separately in men and women. Results: There were no CAC differences between lifestyle and placebo intervention groups in either sex. CAC severity and presence were significantly lower among men in the metformin versus the placebo group (age-adjusted mean CAC severity, 39.5 versus 66.9 Agatston units, P=0.04; CAC presence, 75% versus 84%, P=0.02), but no metformin effect was seen in women. In multivariate analysis, the metformin effect in men was not influenced by demographic, anthropometric, or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy. Conclusions: Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men.

Original languageEnglish (US)
Pages (from-to)52-64
Number of pages13
JournalCirculation
Volume136
Issue number1
DOIs
StatePublished - Jul 4 2017

Fingerprint

Metformin
Life Style
Coronary Vessels
Outcome Assessment (Health Care)
Calcium
Prediabetic State
Coronary Disease
Diabetes Mellitus
Placebos
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risk Management
Coronary Artery Disease
Atherosclerosis
Multivariate Analysis
Age Groups
Demography
Incidence

Keywords

  • clinical trial [publication type]
  • coronary artery disease
  • prediabetic state
  • therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. / for the Diabetes Prevention Program Research Group.

In: Circulation, Vol. 136, No. 1, 04.07.2017, p. 52-64.

Research output: Contribution to journalArticle

for the Diabetes Prevention Program Research Group. / Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. In: Circulation. 2017 ; Vol. 136, No. 1. pp. 52-64.
@article{d357f94ab8984ff280e20305ca21542b,
title = "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium",
abstract = "Background: Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years. Methods: The DPPOS offered periodic group lifestyle sessions to all participants and continued metformin in the originally randomized metformin group. Subclinical atherosclerosis was assessed in 2029 participants with coronary artery calcium (CAC) measurements after an average of 14 years of follow-up. The CAC scores were analyzed continuously as CAC severity and categorically as CAC presence (CAC score >0) and reported separately in men and women. Results: There were no CAC differences between lifestyle and placebo intervention groups in either sex. CAC severity and presence were significantly lower among men in the metformin versus the placebo group (age-adjusted mean CAC severity, 39.5 versus 66.9 Agatston units, P=0.04; CAC presence, 75{\%} versus 84{\%}, P=0.02), but no metformin effect was seen in women. In multivariate analysis, the metformin effect in men was not influenced by demographic, anthropometric, or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy. Conclusions: Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men.",
keywords = "clinical trial [publication type], coronary artery disease, prediabetic state, therapeutics",
author = "{for the Diabetes Prevention Program Research Group} and Goldberg, {Ronald B.} and Aroda, {Vanita R.} and Bluemke, {David A.} and Elizabeth Barrett-Connor and Matthew Budoff and Crandall, {Jill P.} and Dana Dabelea and Horton, {Edward S.} and Mather, {Kieren J.} and Orchard, {Trevor J.} and David Schade and Karol Watson and Marinella Temprosa",
year = "2017",
month = "7",
day = "4",
doi = "10.1161/CIRCULATIONAHA.116.025483",
language = "English (US)",
volume = "136",
pages = "52--64",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium

AU - for the Diabetes Prevention Program Research Group

AU - Goldberg, Ronald B.

AU - Aroda, Vanita R.

AU - Bluemke, David A.

AU - Barrett-Connor, Elizabeth

AU - Budoff, Matthew

AU - Crandall, Jill P.

AU - Dabelea, Dana

AU - Horton, Edward S.

AU - Mather, Kieren J.

AU - Orchard, Trevor J.

AU - Schade, David

AU - Watson, Karol

AU - Temprosa, Marinella

PY - 2017/7/4

Y1 - 2017/7/4

N2 - Background: Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years. Methods: The DPPOS offered periodic group lifestyle sessions to all participants and continued metformin in the originally randomized metformin group. Subclinical atherosclerosis was assessed in 2029 participants with coronary artery calcium (CAC) measurements after an average of 14 years of follow-up. The CAC scores were analyzed continuously as CAC severity and categorically as CAC presence (CAC score >0) and reported separately in men and women. Results: There were no CAC differences between lifestyle and placebo intervention groups in either sex. CAC severity and presence were significantly lower among men in the metformin versus the placebo group (age-adjusted mean CAC severity, 39.5 versus 66.9 Agatston units, P=0.04; CAC presence, 75% versus 84%, P=0.02), but no metformin effect was seen in women. In multivariate analysis, the metformin effect in men was not influenced by demographic, anthropometric, or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy. Conclusions: Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men.

AB - Background: Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years. Methods: The DPPOS offered periodic group lifestyle sessions to all participants and continued metformin in the originally randomized metformin group. Subclinical atherosclerosis was assessed in 2029 participants with coronary artery calcium (CAC) measurements after an average of 14 years of follow-up. The CAC scores were analyzed continuously as CAC severity and categorically as CAC presence (CAC score >0) and reported separately in men and women. Results: There were no CAC differences between lifestyle and placebo intervention groups in either sex. CAC severity and presence were significantly lower among men in the metformin versus the placebo group (age-adjusted mean CAC severity, 39.5 versus 66.9 Agatston units, P=0.04; CAC presence, 75% versus 84%, P=0.02), but no metformin effect was seen in women. In multivariate analysis, the metformin effect in men was not influenced by demographic, anthropometric, or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy. Conclusions: Metformin may protect against coronary atherosclerosis in prediabetes and early diabetes mellitus among men.

KW - clinical trial [publication type]

KW - coronary artery disease

KW - prediabetic state

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85021773256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021773256&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.116.025483

DO - 10.1161/CIRCULATIONAHA.116.025483

M3 - Article

VL - 136

SP - 52

EP - 64

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 1

ER -